Cytokinetics,’s (CYTK) “Outperform” Rating Reiterated at JMP Securities
JMP Securities reissued their outperform rating on shares of Cytokinetics, Incorporated (NASDAQ:CYTK) in a research report released on Tuesday, The Fly reports. JMP Securities currently has a $13.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $17.00. The analysts noted that the move was a valuation call.
CYTK has been the topic of several other reports. Needham & Company LLC reaffirmed a buy rating and set a $22.00 target price on shares of Cytokinetics, in a report on Sunday, September 17th. BidaskClub raised Cytokinetics, from a hold rating to a buy rating in a report on Tuesday, July 25th. Morgan Stanley began coverage on Cytokinetics, in a report on Monday, July 31st. They set an overweight rating and a $24.00 target price on the stock. Zacks Investment Research downgraded Cytokinetics, from a buy rating to a hold rating in a report on Thursday, August 17th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $18.00 target price on shares of Cytokinetics, in a report on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Cytokinetics, presently has a consensus rating of Buy and a consensus target price of $17.64.
Cytokinetics, (NASDAQ CYTK) opened at $7.97 on Tuesday. Cytokinetics, has a twelve month low of $7.00 and a twelve month high of $17.20. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.
In other news, insider Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics, stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total value of $55,124.40. Following the completion of the transaction, the insider now directly owns 17,982 shares of the company’s stock, valued at approximately $232,687.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Bradley Paul Morgan sold 118,330 shares of Cytokinetics, stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $15.00, for a total value of $1,774,950.00. Following the completion of the transaction, the senior vice president now directly owns 63,107 shares of the company’s stock, valued at $946,605. The disclosure for this sale can be found here. Over the last three months, insiders sold 178,223 shares of company stock valued at $2,639,239. Corporate insiders own 7.20% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue bought a new position in shares of Cytokinetics, in the 2nd quarter worth about $109,000. Municipal Employees Retirement System of Michigan bought a new position in shares of Cytokinetics, in the 2nd quarter worth about $132,000. Birchview Capital LP bought a new position in shares of Cytokinetics, in the 3rd quarter worth about $145,000. Piedmont Investment Advisors LLC bought a new position in shares of Cytokinetics, in the 3rd quarter worth about $159,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of Cytokinetics, by 4,464.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 13,036 shares in the last quarter. 71.92% of the stock is owned by hedge funds and other institutional investors.
Cytokinetics, Company Profile
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.